• Launch of Spanish-language Telemedicos USA to serve 58 million Hispanics in the U.S.
• Unique telemedicine model connects specialty physicians with rural care providers, patients
• MIHI building nationwide telemedicine network focusing on needs of underserved Americans

Medical Innovation Holdings, Inc. (OTC: MIHI) continues to transform the health care industry with the launch of Telemedicos USA, a Spanish-language health care platform designed to deliver much-needed services to the estimated 58 million Hispanics living in the United States. This minority population often experiences disparities when seeking out health care access because of insurance issues, language barriers and the lack of medical clinics located in rural areas of the country. Telemedicos USA was created to serve this demographic, the largest minority group in the United States, and its growing population base.

“This was a natural evolution for us,” MIHI CEO Jake Sanchez, stated in a news release. “We purposefully positioned MIHI for this market because we understand the nuances of providing services to such an ethnically diverse group that make up the Hispanic community.”

Telemedicos USA will use primary care, on-demand telemedicine services paired with 3PointCare’s specialty network of doctors, providing unparalleled access to health care. Telemedicos USA also will offer pharmaceuticals, alternative medicines and patient portals to create a cloud-based, electronic medical records (EMR) that travels with the patient.

MIHI offers a unique, proprietary telemedicine platform that fills a critical health care need facing millions of Americans living in rural, medically underserved areas. The company’s business model is designed to greatly increase not only health care access for people who struggle to find medical care, but administrative support to physicians in the field and the ability to grow their rural practices through more product and service offerings. This well-rounded approach, created through a variety of subsidiaries, serves as the foundational basis of a comprehensive health care-centric business ecosystem. MIHI intends to continue its expansion throughout the United States as it becomes the go-to primary health care resource for a long neglected section of the nation’s underserved population.

For more information, visit the company’s website at www.MedicalInnovationHoldings.com

Let us hear your thoughts: Medical Innovation Holdings, Inc. Message Board

• HighCom’s website showcases its two divisions – HighCom Armor Solutions, Inc., and BlastGard Technologies, Inc.
• The Department of Homeland Security has approved and certified the company’s ballistic armor and protective equipment
• The company maintains its ISO 9001:2008-certfied Quality Management System and supplies over 20,000 pieces of armor per month

A global leader in blast effects mitigation solutions, HighCom Global Security, Inc. (OTC: HCGS) has announced the launch of a new website that represents its security and defense products brand, pursuit of innovation, and its effective acquisition strategy. The site is a portal into the company’s brand and its services. It demonstrates what has enabled HighCom to reach a level of sustained growth and give customers and investors unique opportunities in this highly specialized field.

The website incorporates HCGS’s two main businesses. HighCom Armor Solutions, Inc. is a designer and tester of body armor and personal protective equipment; it’s also a leader in manufacturing and distributing these vital products, including hard and soft armor, to federal, state, and local law enforcement agencies. The company serves several military branches as well. Body armor products are sold directly on the website, making it easy for agencies to procure the equipment they need to protect personnel at all times.

A key part of HighCom is now BlastGard Technologies, Inc., a manufacturer and supplier of proprietary blast mitigation materials. Its BlastWrap® technology, used on new products and to retrofit others, can suppress the effects of blasts and the fires that can result. The technology has been used in structural walls, commercial aircraft, cargo containers, aboard naval vessels, and in fuel tanks. It’s also been implemented aboard offshore platforms, in fireworks plants, and by explosives manufacturers. The Safety Act certified product is on the “Approved Products List for Homeland Security” and approved by the General Services Administration.

HighCom Global Security has had much success in 2017, introducing new products to its line of armor, bullet proof vests, shields, helmets, plates, rifle armor, vest attachments, ballistic blankets, bags/pouches, and civilian armor systems. The latest additions to the product line include the Level IIIa elite high-performance soft armor panel, and the Level III++ multi-curve hard armor ballistic plate. In addition, the company has undergone a corporate restructuring that recently added Craig B. Campbell as HCGS’s chief executive officer. The reorganization also included a name change, formation of a new board of directors, and division of the business into two distinct entities. HighCom Armor Solutions now serves the global market of personal protective equipment, while BlastGard is devoted to blast mitigation technology serving a diverse global market.

Department of Defense contracts have represented a major portion of HighCom’s business. It supplied nearly a million pieces of ballistic armor over about a decade. Founded in 1997, the company has stepped up its output capacity and can now supply over 20,000 pieces of armor monthly. Its ISO 9001:2008-certfied Quality Management System continues to guarantee that all products manufactured and delivered by HCGS are approved by the International Organization of Standards, guaranteeing compliance and effectiveness. The company’s quality system has been in place since 2005.

For more information about the company, visit its website at www.HighComGlobal.com.

Let us hear your thoughts: HighCom Global Security, Inc. Message Board

• Topical product technology protected by patents
• Targeting $80 billion global skin care and dermatology market
• Product sales in China

Outsourcing has been the status quo in the pharmaceutical industry since long before the term gained notoriety. Large pharmaceutical and cosmeceutical companies, under pressure from rising R&D costs, have been farming out that part of their businesses for a long time now in an attempt to reduce costs. This approach also has the advantage of offloading the costs of patenting to the outsourcee. To obtain the advantages of adopting new technology, patent protection is vital to avoid copycatting. That is why the technology developed by Skinvisible, Inc. (OTCQB: SKVI), through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., has been adopted by pharmaceutical and cosmeceutical companies since 1999. The Las Vegas, Nevada–based R&D company developed Invisicare® technology, which can be used to revitalize or create new medical or skin care products, allowing a company that licenses Skinvisible’s formulations to sell their own patented product and combat generic competitors.

Invisicare is a patented polymer delivery system that improves the delivery of topically applied skin care products, thereby enhancing the efficacy of the active ingredients. The unique process extends the time the product remains active on the skin and is specifically formulated to transport active ingredients that are insoluble in water without using alcohol, silicones, waxes, or other organic solvents.

Products utilizing Invisicare have been effective at bonding active ingredients to the skin for up to four hours and longer. Invisicare is non-occlusive; it allows normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants. When topically applied, products formulated with Invisicare adhere to the skin’s outer layers, forming a protective bond, resisting wash-off, and delivering targeted levels of therapeutic or cosmetic skin care agents to the skin. This allows enhanced delivery performance for a variety of topicals, resulting in improved efficacy, longer duration of action, reduced irritation and lower dosage of active agent required. The “invisible” polymer compositions that make up Invisicare wear off as part of the natural exfoliation process that removes the skin’s outer layer of cells.

With a $80 billion global dermatology market and a $30 billion global skin care over-the-counter (OTC) market, the patented polymer delivery system for topical products developed by Skinvisible, obviously, has many, many possible applications. The company has already inked an agreement (http://dtn.fm/ePdz3) with a large, well-known Canadian medical marijuana company: the first to attain ‘unicorn’ status in the industry. Under the agreement, the MMJ company will distribute Skinvisible’s topical products in Canada. The agreement covers two distinct product lines made with Skinvisible’s Invisicare technology. Skinvisible will develop unique topical hemp-based products to be launched by Canopy Hemp Corporation in Canada and the United States. In addition, the agreement includes potential cannabis-based topical products using Invisicare® technology when and if federal regulations permit CBD- or THC-infused topical products for sale in Canada.

While it continues to expand its licensing relationships, Skinvisible is developing its own line of OTC products, which is available for out-licensing. The 40+ products include antimicrobial hand sanitizers and skin care products for acne, skin fungi and atopic dermatitis. Skinvisible has also developed its own line of anti-aging products under the Kintari® brand (day cream, night cream, hand & body lotion, sunscreen and DermSafe), all available on www.Kintari.com. Kintari is a wholly owned subsidiary of Skinvisible.

In June 2017, the company announced that it had completed its first international sale of DermSafe® hand sanitizer in China (http://dtn.fm/83Enw) through its agent, InterSpace Global, Inc. The agreement with InterSpace Global facilitates the export of Skinvisible’s OTC products to mainland China, Hong Kong, Macau, Taiwan, Singapore, Malaysia, Thailand and Korea. In the beauty-conscious Chinese diaspora, Skinvisible is on track to repeat its U.S. success story.

For more information, visit the company’s website at www.Skinvisible.com

Let us hear your thoughts: Skinvisible, Inc. Message Board

• Current cryptocurrency market cap is $155 billion
• BLKCF offers investors a basket of blockchain startups, small caps and blue chip holdings from team of industry pioneers, entrepreneurs
• Company offers investment opportunities in initial coin offerings (ICOs)

Global Blockchain Technologies Corp. (OTC: BLKCF) (TSX.V: BLOC) (FSE: BWSP) has named a new management team (http://dtn.fm/JP8t2) including Steven Nerayoff, chairman; Rik Willard, CEO; Shidan Gouran, president and COO; and Kyle Kemper, chief strategy officer. An advisory board to the company was also named. The goal is to offer a team of experienced managers to the emerging blockchain industry, bringing a unique opportunity to investors in the cryptocurrency market. Cryptocurrencies are seen as having a market cap of $155 billion by CoinMarketCap.com (http://dtn.fm/J7Xfu).

BLKCF is a Canadian investment banking company offering investors a basket of holdings within the blockchain realm, managed by a team of executives who have had a significant impact on the rise of blockchain. The company’s goal is to become the first publicly traded company with vertically integrated originators of top-tier blockchains and digital currencies. Interested investors can become exposed to cryptocurrencies through BLKCF. The company is also looking to list in Asia and Australia in order to offer 24-hour tradability.

The company mixes blue chip holdings such as bitcoin and ethereum with numerous top-tier smaller cap crypto holdings. The new management team for BLKCF includes creators of the initial coin offering (ICO) revolution. Added value of BLKCF to investors is driven by its offerings as an in-house innovation incubator, presenting initial capital technical development and legal support. The company is also able to bring new companies to market with an ICO.

The new ‘core’ team of the company is seeking to incubate about 6-12 “tokens” from startups to existing small cap companies, which it defines as those having caps of $100 million-$1 billion. In return for its initial funding and guidance, BLKCF would retain a major equity stake in those firms. All of this makes BLKCF a unique investment opportunity providing a means to easily investable blockchain exposure. Its combination of mature companies in the cryptocurrency market with small cap “tokens” and startups provides an effective platform for meaningful returns, BLKCF says.

New Chairman Nerayoff, a pioneer in the blockchain industry, is a serial entrepreneur who founded six companies in Silicon Valley and New York. Willard, CEO, is also a pioneer in blockchains and founded the Agentic Group LLC. Gouran, president, was founder of Nuovotel, one of the largest VoIP services. Kemper, CSO, is the executive director of the Blockchain Association of Canada.

Named to the company’s advisory board were Jim Rogers, Jeff Pulver, Gary Rubinoff, Michael Terpin, David Drake and Manie Eagar.

For more information, visit the company’s website at www.GlobalBlockchain.io

• Poised to disrupt sciences sample preparation market estimated at $6 billion
• Nearly 300 patented enabling technology platform products installed at more than 150 sites worldwide
• Two patents awarded in China for Ultra Shear Technology used in wide range of industrial applications, including “clean foods”
• Finalist in prestigious 2017 R&D 100 Awards recognizing top revolutionary technologies
• Technology being used as part of the U.S. “Cancer Moonshot” initiative

Pressure BioSciences, Inc. (OTCQB: PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

For more information, visit the company’s website at www.PressureBioSciences.com

• Largest mini-casino operator in Washington
• Increasing revenues and profits
• Better odds than betting in a casino

Americans love casino gambling. In near record numbers, over 81 million people visited U.S. casinos in the 12-month period ended in the spring of 2017 (http://dtn.fm/jFUn2). From nickel slots to blackjack, almost everyone placed some form of wager, even though the house always has the edge. With such a penchant for casino gambling, the U.S. gaming industry is poised for another year of growth.

Blackjack has the best odds of winning, with a house edge of one to two percent in most casinos, notwithstanding the casino’s built-in advantage between the promised payout and the inherent odds of the game. The house never takes the extra risk; the bettor does. Popular slot machines have the lowest odds of winning, with a house edge of 10 percent or more. Despite the thrill and excitement, walking away a winner at a casino is a long shot. Rather than betting “in” casinos, better odds can be found betting “on” casinos. Well-run casinos are money pumps, and a more likely winning bet is buying a gaming company’s stock at the biggest casino of them all, the stock market.

Each year, gaming revenues in the U.S. yield more profits than the movie and recorded music industries combined. Even the combined revenue of the four major U.S. professional sports leagues is dwarfed by earnings from the commercial casinos industry. Casino stocks have surged this year with the big names leading the way. A smarter bet may be to look at smaller casino operators that enjoy similar ratios but haven’t made big moves yet.

Las Vegas-based Nevada Gold & Casinos, Inc. (NYSE MKT: UWN) is just such an operator. Nevada Gold & Casinos finances, develops, owns and operates gaming properties and projects in multiple U.S. locations. The company’s Washington Gold is the largest operator of mini-casinos in Washington. Nevada Gold also owns a slot route operation in Deadwood, South Dakota, and the Club Fortune Casino in Henderson, Nevada, with 540 slot machines, seven table games, a poker room, two bars, an entertainment lounge and a sports book. Washington’s mini-casinos have limited game options based on state law, but most offer multiple card games. Combined, Nevada Gold’s Washington facilities have over 120 table games including Blackjack, Pai Gow Poker, Baccarat, Spanish 21, Blackjack – Double Action, Ultimate Holdem, and Three and Four Card Poker. Additional banked table games are permitted along with poker and pull tabs. The company’s 24-hour Washington Gold casinos include full service restaurants with bars and collectively employ 1,100 people.

In July, Nevada Gold & Casinos announced financial results for the fourth quarter and year ended April 30, 2017 (http://dtn.fm/T63qV). For the fourth quarter of fiscal 2017, the company reported net revenues of $19.8 million and net income of $1.2 million, or $0.07 per share. For the fiscal year 2017, the company reported net revenues of $74.6 million, compared to $70.2 million in fiscal year 2016. The Board of Directors authorized a share repurchase program of $2.0 million in 2016 and completed the buy back at favorable prices. The Board has also approved an additional $2.0 million share buyback, a strong indication that the company believes it’s undervalued in the market.

Since the stock market’s recovery began in 2009, major gambling companies in the U.S. have beaten the broader market several fold. Expanding profit potential has triggered a rush within the gaming industry as companies buy up other players to capture as much market share as possible. This could bode well for Nevada Gold as a potentially attractive target. As a well-run profitable gaming company, Nevada Gold may also provide outsized returns of its own and deliver much better odds to pocket casino cash.

For more information, visit the company’s website at www.NevadaGold.com

• Canadian marijuana market seen as C$2.8 billion by CY2020, a 30% YOY gain, research study projects.
• Extracts/oil from cannabis (CBD) sales by CY2020 will surpass dried marijuana by wide margin.
• Marijuana seen as being fully legalized in Canada by July 2018.

Algae Dynamics Corp. (OTCQB: ADYNF) sees opportunity and greater market share in a soon to be legalized marijuana industry in Canada, where registered clients are estimated to grow to 715,000 by CY2020, cumulatively purchasing 124,443 kilograms (kg) of dried medical marijuana annually, a 31% YOY increase, a study by Mackie Research found (http://dtn.fm/Fa7vW). If the Colorado model remains true, some 45% of those buyers will switch by 2018 from dried medical marijuana to marijuana extracts/oil, creating a market of 239,998 liters in extracts/oil alone.

That’s good news for ADYNF, a producer of health products and nutraceuticals that utilizes extraction of cannabis, hemp, and algae oils in its products. It is a development-stage company with a portfolio of intellectual property and a signed agreement with a Licensed Producer. ADYNF is an Ontario, Canada-based company, but it is publicly traded in the U.S. Because it is located in Canada, it is free of all exposure to any U.S. federal regulations or restrictions of cannabis.

Legalization of marijuana in Canada is widely expected by July 2018 (http://dtn.fm/To4tc). If that happens, Mackie research projects that the Canadian market for both dried marijuana and extracts/oil would be an estimated C2.8 billion in CY2018, a 30% YOY increase. By that year, sales of extracts/oil would surpass revenues from dried marijuana by C1.687 billion to C1.113 billion.

ADYNF collaborates with the University of Waterloo and University of Western Ontario in research, formulations and product development, with the company maintaining patent rights on the research findings. The goal is to develop premium, patented health products.

Most recently, in collaboration with the University of Western Ontario, it was found that higher levels of the brain chemical GABA can help reverse in adults the negative effects of THC-infused marijuana ingested when in adolescence. The findings, published in Nature Scientific Reports (http://dtn.fm/J2dqa), earned ADYNF international press recognition.

For more information, visit the company’s website at www.AlgaeDynamics.com

Let us hear your thoughts: Algae Dynamics Corp. Message Board

• The global online travel market is estimated to reach $1,091 billion by 2022
• Growth of online travel driven by social media, the Internet, disposable income, mobility
• Direct spending by domestic and international travelers in U.S. averaged $2.7 billion a day
• Proprietary back-end software opens distinctive online world travel portal that saves customers money

Cache Elite Inc. (OTC: ILUS) is a forward-thinking technology and service provider. The company provides homeowners with the latest in 3D designs, decorative hardware (http://www.eliteknobs.com), and travel and vacation services. Its foray into travel-related services can be found at the TripWitz website (http://www.tripwitz.com) where its proprietary back-end software, called Internet Travel Management Software, helps TripWitz provide its customers with a distinctive, cost-effective and perfect travel experience that sets it apart from other online travel agencies such as Expedia and Travelocity.

TripWitz provides real-time, dynamically packaged vacation quotes that include airfare, hotels, villas, ground transportation and activities. Every client searching for a smarter way to travel will find TripWitz is able to cut out the stress and frustrations found with other online travel agents. The company provides its intuitive travel services to clients searching vacations possibilities at more than 20,000 destinations around the globe.

TripWitz contracts with over 500,000 hotels and connects with the world’s airlines through Google’s ITA Gateway software that allows for advanced availability solutions to satisfy millions of queries per second at the lowest possible fares. Seasonal rate fluctuations for many travel services, including ground transportation options, are included in the company’s software, giving clients the best possible rates. TripWitz prides itself on giving users a friendly vacation experience that includes access to an experienced vacation destination specialist. Customers are never left to fend for themselves at any point of their vacation experience. TripWitz is also accepting Bitcoins, the international cryptocurrency, as payment for not only flights but vacations as well.

A new report published by Allied Market Research projects the global online travel market will reach an estimated $1,091 billion by 2022, with the Asia-Pacific region expected to witness the highest growth during the forecast period. Travelers are looking for sound help in making travel decisions that fit within their budgets. Younger travelers, those within the 21-31 year age bracket, are seen as a more mobile generation, using social media and smartphones for many of their travel planning and booking needs.

TripWitz is an accredited member of the CCRA (Travel Commerce Network), which connects the company to over 180,000 properties worldwide. TripWitz is also an ARC approval agency. ARC accredited agencies are the most select group of dedicated professionals in the U.S. travel industry and are recognized as having met stringent financial, personnel and security requirements.

The official press release announcing the recent launch of TripWitz can be found at the following link: Cache Elite Inc. (ILUS) Unveils New Venture Into the $341 Billion Travel Industry

For more information, visit the company’s website at www.CacheElite.com

Let us hear your thoughts: Cache Elite Inc. Message Board

• Demand for Electric Vehicles is Growing
• Lithium Producer Valuations are on the Rise
• Junior Valuations Likely to Follow

The die is cast. There is no turning back the legion of electric vehicles (EVs) now making inroads in our cities. Americans are warming up to the idea of driving EVs. As a result, EV sales, running at a rate well above 40 percent compared to 2016, could reach 200,000 in 2017. Tesla, of course, is in the vanguard of this EV invasion, followed closely by General Motors (GM) and Toyota; but practically every other auto manufacturer, including BMW, Fiat, Ford, Honda, Hyundai, Mercedes, Nissan, Porsche, Volkswagen and Volvo, has gotten on board the EV wagon. This upsurge in EV sales is driving demand for automotive batteries and the lithium that powers them, which makes the lithium properties held by 92 Resources Corp. (TSX.V: NTY) (OTCQB: RGDCF) (FSE: R9G2) increasingly precious resources.

A recent article on NetworkNewsWire highlights how Lithium is Fuelling the New Millennium (http://dtn.fm/gZV5F). Apart from its use in automobiles, lithium is an essential component of the batteries that power the 8 million smart phones and other mobile devices now in use around the globe. Consequently, while the hunger for lithium will fluctuate in the short term; in the longer term, it is only likely to increase, as market signals indicate. Valuations of the leading lithium producers have been rising steadily. FMC Corp (NYSE: FMC) has appreciated by 87% over the past year; Sociedad Quimica y Minera de Chile (NYSE: SQM) has shot up by over 109% and Albemarle Corporation (NYSE: ALB) has climbed some 62%.

As stock prices of the senior mining companies fully encapsulate the promising outlook for lithium, it is only a matter of time before the attention turns to junior exploration companies like 92 Resources. The company presently holds two lithium rich properties, at Hidden Lake and at their Corvette Property in Quebec. The Corvette Property is geologically situated within the Guyer Greenstone Belt and consists of 76 claims, totaling 3,891 hectares. The Corvette project has returned high-grade samples of 3.48% and 7.32% Li20 from spodumene bearing pegmatite exposed at surface. The Hidden Lake Lithium Property, located approximately 40 km northeast of the city of Yellowknife, NT, consists of two mineral claims, totaling approximately 1,100 hectares. It is highly prospective for spodumene-bearing lithium pegmatites, with samples indicating between 1.37% and 3.01% Li2O. The very high grades of lithium have been attributed to observed concentrations of coarse-grained spodumene and crystals of up to 36 inches long were also noted, with visual estimates across the dyke(s) in some places of 20 to 35%.

However, there’s more to 92 Resources than Hidden Lake and Corvette. The company recently acquired three new properties, believing it’s critical to maintain a pipeline of additional high quality, early staged lithium pegmatite projects, each with the potential as stand-alone properties. The new deposits are sited at Corvette, Eastmain, and Lac du Beryl, and consist of 115 mineral claims on a combined 14,710 acres, all rich in pegmatite. Pegmatite is a type of crystal-heavy igneous rock, and is a good source of ‘hard rock’ lithium, which represents about one-third of all global reserves.

For more information, visit the company’s website at www.92Resources.com

Let us hear your thoughts: 92 Resources Corp. Message Board

• Delivery technology with application to all non-psychoactive cannabinoids
• Company is an enabler rather than competitor to hemp oil producers
• Revenue from licensing DehydraTECH oral digestion technology

Thanks to Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), there’s no need for a spoonful of sugar to help the medicine go down. This innovative biotech has developed technology that masks the strong taste and odor of hemp oil products, eschewing the need for artificial sweeteners, which tend to come with their own fallout to heart and health. Lexaria’s DehydraTECH oral digestion technology is a ‘back office’ process that solves the taste and odor issues that confront all hemp oil producers. With the hemp oil market set to grow 38 percent annually for the near future, Lexaria is well positioned to benefit from the expansion as an enabler rather than competitor. The company intends to license its technology to hemp oil producers, whose numbers continue to rise, and has already tightened its grip on the market with a number of patent filings and registrations.

Hemp might be palatable to a troglodyte, but since it ‘tastes like a handful of grass and dirt’, according to the ‘Made by Hemp’ blog (http://dtn.fm/y1OII), a modern homo sapien, accustomed to his burger and fries, is unlikely to find it palatable. The obvious solution is to complement the intake of hemp with sugars or sweeteners. However, while sugars occurring naturally in fruits and other foods will usually pose no health problem, processed sugar and artificial sweeteners are quite the opposite. “Refined, concentrated sugar consumed in large amounts rapidly increases blood glucose and insulin levels, increases triglycerides, inflammatory mediators and oxygen radicals, and with them, the risk for diabetes, cardiovascular disease and other chronic illnesses,” according to Harvard Health (http://dtn.fm/UhVt0). Moreover, artificial sweeteners can be addictive. One pre-clinical study worryingly demonstrated that rodents, when given a choice between intravenous cocaine and oral saccharine, mostly chose the saccharine.

The prospects for Lexaria’s DehydraTECH technology are decidedly upbeat. According to this Forbes piece (http://dtn.fm/CbE4N), the hemp-derived cannabidiol (CBD) market is growing at a steady clip, citing statistics by the Hemp Business Journal that show sales of $90 million in 2015 rising to $450 million by 2020. That 38% CAGR will, undoubtedly, be boosted if and when legalization of recreational cannabis becomes a reality in Canada on July 1, 2018. Lexaria is poised to ride that wave to the crest. At present, the company is in negotiations with major cannabinoid companies to license its technology. The smallest deal with any one of these could increase revenues by over $1 million; the largest could increase them by much, much more, as noted by CEO Chris Bunka in a recent interview (http://dtn.fm/mu1ZI). Since Lexaria is employing a lucrative licensing model that is likely to yield 90-100% of revenues as profit, the bottom line won’t be far below the revenue figure. The company expects to have its first major agreement wrapped up by the end of the year.

Presently, Lexaria is the only company in the world that has been awarded a patent for the improved (oral or ingestible, including pills) delivery of all non-psychoactive cannabinoids. Patents have been awarded in the U.S. and Australia and are pending in 40 more countries. This puts the company in the unusually advantageous position of owning proprietary technology that can deliver a vast range of non-psychoactive cannabinoid-based drugs. Rather than being a competitor to clinical stage biotech companies, Lexaria is an enabler by offering its molecular delivery technology for licensing.

The results are beginning to show. So far in 2017, revenues have exceeded the total for all of 2016. That trend is likely to continue, since Lexaria’s DehydraTECH technology offers oral digestion of hemp oil in a most delightful way.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board